Kenvue (KVUE) shareholders will vote on Kimberly-Clark's (KMB) $48.7 billion acquisition proposal on Thursday, Jan. 29. The merge deal, announced in November 2025, would create a consumer health and wellness powerhouse, combining iconic brands like Band-Aid, Tylenol, and Listerine with Huggies, Kleenex, and Cottonelle.
The transaction offers shareholders $21.01 per share in total consideration, representing a meaningful premium over current trading levels of around $17. Yet with KVUE stock trading roughly 18% below the deal price, investors must weigh the arbitrage opportunity against execution risks, including regulatory hurdles and shareholder approval.
